Colorectal Cancer - Krazati with or without Erbitux in Mutated KRAS G12C
Colorectal Cancer – Krazati with or without Erbitux in Mutated KRAS G12C
Background Adagrasib, also called “Krazati”, is a tablet taken by mouth which inhibits KRAS G12C mutation. It has shown clinical activity in pretreated patients with several tumor types, including colorectal…